Bristol-Myers Squibb stock holds near consensus target as investors digest Q2 2026 earnings
Published on 08/28/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb Inc. (ISIN US1078421011) stock is trading in the mid-$60 range on August 28, 2026, with recent data showing shares opening at $66.93 on the New York Stock Exchange as investors continue to assess the company’s latest quarterly results and earnings outlook.
Q2 2026 numbers frame the earnings story
Recent market data compiled by a financial portal shows Bristol-Myers Squibb shares opening at $66.93 on a recent trading day, a level broadly consistent with the stock’s current consensus landscape and placing the shares close to the mid-$60 zone that many analysts use as a reference point. This price context matters because it ties directly to how investors interpret the company’s Q2 2026 performance and forward expectations.
One same-day comparison overview for pharmaceutical stocks lists Bristol-Myers Squibb with a recent share price of $67.14, a one-day move of -0.6%, and a 52-week range from $42.52 to $68.64. That combination indicates the stock is trading near the upper end of its one-year range while still below the recent 52-week high, underscoring that much of the recovery from the low-$40s has already occurred but that the stock has not broken out to new highs yet. For investors, the proximity to the 52-week high at $68.64 provides a concrete technical reference in relation to the current $67.14 quotation.
The same pharmaceutical comparison summary also highlights Bristol-Myers Squibb’s valuation and earnings power with a market capitalization of $137.16 billion and a current price-to-earnings ratio of 12.10, underpinned by trailing earnings per share of $1.60 and forward-looking figures. Those metrics suggest a large-cap profile with moderate valuation by sector standards, which can be a key factor for investors considering the balance between growth expectations and downside risk.
On the fundamental side, the July 15, 2026 Q2 2026 snapshot in the comparison overview shows that Bristol-Myers Squibb generated revenue of $11.74 billion in Q2 2026, with consensus revenue for Q2 2026 indicated at $12.97 billion. That implies a shortfall of $1.23 billion versus the comparison’s listed consensus estimate, pointing to a revenue miss in that quarter even though the absolute revenue figure remains substantial. The earnings line for the same period shows EPS of $1.62 in Q2 2026 versus a prior figure of $1.60, a modest increase of $0.02 that demonstrates incremental earnings growth even in the face of softer-than-expected top-line performance.
The Q2 2026 comparison numbers, dated July 15, 2026 and well within the freshness window relative to August 28, 2026, provide a timely lens on how Bristol-Myers Squibb’s latest quarter stacked up against expectations. Revenue at $11.74 billion in Q2 2026 versus $12.97 billion in listed consensus highlights the importance of pipeline progress and portfolio resilience to support future growth, while the small EPS uptick from $1.60 to $1.62 reinforces that cost management and margin discipline helped stabilize profitability despite the softer revenue.
Analyst stance and consensus targets
Several recent institutional activity summaries featuring Bristol-Myers Squibb mention that, based on aggregated data in the same period, the stock carries a consensus rating of Moderate Buy and an average target price of $66.06. With shares opening at $66.93 and other real-time comparisons indicating a price of $67.14, Bristol-Myers Squibb stock is currently trading slightly above the $66.06 average target. This small premium of around $1 to $1.08 relative to the average target suggests that the market is pricing in a degree of optimism beyond the median analyst view, while remaining within a narrow band around that target.
The Moderate Buy consensus rating reflects a balance between positive and more cautious voices within the analyst community. The revenue miss versus the $12.97 billion consensus figure for Q2 2026 likely tempers enthusiasm, even as the EPS improvement from $1.60 to $1.62 and the enduring strength of the company’s core franchises lend support to the earnings story. For many investors, the combination of a large market cap of $137.16 billion, a price-to-earnings ratio of 12.10, and a stock price trading close to the $66.06 average target frames Bristol-Myers Squibb as a major pharmaceutical name in a consolidation phase rather than in a high-growth acceleration phase.
Institutional flows also play into sentiment. Recent filings summarizing positions taken by various asset managers mention new stakes in Bristol-Myers Squibb at price levels aligned with the mid-$60 region. While the exact portfolio strategies differ, the presence of new positions and adjustments at these levels provides a tangible data point that some professional investors see value in the current range, even if the upside potential implied by the Moderate Buy rating and $66.06 target is relatively modest compared with more aggressive growth stories elsewhere in healthcare.
Pipeline and portfolio context
Bristol-Myers Squibb has long been known for its portfolio in oncology, immunology and cardiovascular disease, among other therapeutic areas. The Q2 2026 revenue figure of $11.74 billion sits on top of a diversified product base that includes key brands in cancer and autoimmune disease, which often underpin recurring revenue streams and provide resilience against single-product volatility. While the comparison overview does not break down revenue by product line, the aggregate figure and its relationship to the $12.97 billion consensus estimate highlight that the company’s existing portfolio, rather than one-off events, drove performance in the quarter.
The modest EPS increase from $1.60 to $1.62 in Q2 2026 suggests that Bristol-Myers Squibb managed to maintain or slightly enhance margins through cost control and operational efficiency. In the pharmaceutical industry, small changes in EPS can reflect meaningful shifts in R&D spend, launch costs, and pricing dynamics across markets. The ability to grow EPS even when revenue trails consensus indicates that management’s focus on productivity and disciplined spending helped offset some of the top-line pressure.
From a pipeline perspective, investors often look beyond a single quarter’s revenue miss to evaluate longer-term potential in late-stage trials and recently launched medications. The Q2 2026 comparison numbers, in this context, serve as a benchmark rather than a verdict: they show that at $11.74 billion in revenue and $1.62 EPS, Bristol-Myers Squibb retains substantial earnings capacity to fund R&D and strategic transactions. The company’s scale, reflected in the $137.16 billion market cap and 12.10 price-to-earnings ratio, underlines that it remains one of the major global players in branded pharmaceuticals.
Valuation, risk and sector backdrop
Valuation metrics drawn from the same comparison overview give investors concrete yardsticks for Bristol-Myers Squibb’s risk-reward profile. A price-to-earnings ratio of 12.10 is lower than many high-growth biotechnology names and signals a market view that future earnings growth may be more measured, but also that the downside could be cushioned by existing cash flows and established brands. When combined with a market capitalization of $137.16 billion, the company’s valuation points to a mature, defensive profile within the pharmaceutical sector.
The Q2 2026 revenue miss versus the $12.97 billion consensus figure is a clear reminder that even large, diversified pharmaceutical companies face challenges in meeting market expectations, whether due to competition, pricing pressure or launch timing for new treatments. However, the EPS increase from $1.60 to $1.62 and the stock’s position near the upper end of its $42.52 to $68.64 52-week range suggest that the market sees more than just short-term hurdles. For many investors, the key question becomes whether the company’s pipeline and strategic initiatives can convert into sustained top-line growth to complement the earnings stability already demonstrated.
Sector dynamics also play a role. In an environment where interest rates and macroeconomic factors influence risk appetite, a large-cap pharmaceutical stock with a Moderate Buy consensus, a $66.06 average target, and a valuation anchored at a 12.10 price-to-earnings ratio can be seen as part of a broader defensive allocation. The stock’s recent trading around $66.93 to $67.14 shows that while there is not a pronounced rally on the back of Q2 2026 numbers, there is also no pronounced selloff, reinforcing the picture of a name being held and adjusted within portfolios rather than rapidly traded on short-term news alone.
Representative product: oncology portfolio
Within Bristol-Myers Squibb’s business model, oncology remains a core pillar. The company’s cancer portfolio, which includes immuno-oncology agents designed to harness the body’s immune system to fight tumors, contributes significantly to the $11.74 billion revenue figure reported for Q2 2026. These therapies often command premium pricing due to their clinical impact, which helps support overall margin performance and underpins the modest EPS increase from $1.60 to $1.62 observed in the comparison overview.
The oncology franchise is also central to investor expectations embedded in the $12.97 billion consensus revenue estimate for Q2 2026. When quarterly revenue falls short of that benchmark, as it did with the $11.74 billion figure, market participants may interpret the gap as a signal that growth in key cancer indications is progressing more slowly than anticipated or that competitive pressures are stronger than modeled. At the same time, the durability of these products in clinical practice means that revenue streams can be more stable over time, which helps explain why the stock’s valuation and trading range remain relatively steady despite the miss.
Stock level and trading context
As of the latest data on August 28, 2026, Bristol-Myers Squibb stock is associated with recent opening prices in the $66.93 to $67.14 band on the New York Stock Exchange, with the $67.14 figure tied to a one-day change of -0.6% and a 52-week range spanning $42.52 to $68.64. That places the shares marginally above the current $66.06 average target price cited in consensus data and close to the 52-week high at $68.64, giving investors a clear sense of where the stock stands within its recent trading history.
For US retail investors, the practical takeaway is that Bristol-Myers Squibb stock currently trades as a large-cap pharmaceutical name with Q2 2026 revenue of $11.74 billion versus $12.97 billion in listed consensus, EPS rising from $1.60 to $1.62, and a market capitalization of $137.16 billion supporting a price-to-earnings ratio of 12.10. The shares trade on the New York Stock Exchange in US dollars, with recent price action clustered in the mid-$60s and framed by a 52-week range between $42.52 and $68.64.
Read more
More on Bristol-Myers Squibb stock
Fact box
Company: Bristol-Myers Squibb Inc.
ISIN: US1078421011
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 28, 2026): $67.14 USD
Market cap: $137.16 billion (as of August 28, 2026)
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
